Immune monitoring technology primers

Read the articles published monthly by the SITC Immunotherapy Biomarkers Task Force

Due to advances in cancer immunotherapy, including positive results from clinical trials testing new agents and combinations, emerging new technologies for measuring aspects of immunity, and novel candidate biomarkers from early phase trials, the SITC Immune Biomarkers Task Force has reconvened to review the state of the art, identify current hurdles to further success and to make recommendations to the field.

Reviewed by the members of the SITC Immune Biomarkers Task Force, these brief primers highlight important aspects of both standardized and novel technologies available in clinical trial settings.

Advertisement